Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.

Hurwitz, ME; Cho, DC; Balar, AV; Curti, BD; Siefker-Radtke, AO; Sznol, M; Kluger, HM; Bernatchez, C; Fanton, C; Iacucci, E; Liu, Y; Nguyen, T; Overwijk, W; Zalevsky, J; Tagliaferri, MA; Hoch, U; Diab, A

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索